AU2001248314A1 - Use of Oprl lipoprotein from pseudomonas as a Th1 inducing natural adjuvant for heterologous antigens - Google Patents
Use of Oprl lipoprotein from pseudomonas as a Th1 inducing natural adjuvant for heterologous antigensInfo
- Publication number
- AU2001248314A1 AU2001248314A1 AU2001248314A AU2001248314A AU2001248314A1 AU 2001248314 A1 AU2001248314 A1 AU 2001248314A1 AU 2001248314 A AU2001248314 A AU 2001248314A AU 2001248314 A AU2001248314 A AU 2001248314A AU 2001248314 A1 AU2001248314 A1 AU 2001248314A1
- Authority
- AU
- Australia
- Prior art keywords
- pseudomonas
- heterologous antigens
- natural adjuvant
- inducing natural
- oprl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004895 Lipoproteins Human genes 0.000 title 1
- 108090001030 Lipoproteins Proteins 0.000 title 1
- 101700046937 OPRL1 Proteins 0.000 title 1
- 241000589516 Pseudomonas Species 0.000 title 1
- 230000000240 adjuvant Effects 0.000 title 1
- 239000002671 adjuvant Substances 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000038129 antigens Human genes 0.000 title 1
- 108091007172 antigens Proteins 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00200589.0 | 2000-02-18 | ||
EP00200589 | 2000-02-18 | ||
PCT/EP2001/001673 WO2001060404A2 (en) | 2000-02-18 | 2001-02-13 | Use of opri lipoprotein from pseudomonas as a th1 inducing natural adjuvant for heterologous antigens |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2001248314A1 true AU2001248314A1 (en) | 2001-11-08 |
AU2001248314B2 AU2001248314B2 (en) | 2004-08-19 |
Family
ID=8171051
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001248314A Ceased AU2001248314B2 (en) | 2000-02-18 | 2001-02-13 | Use of Oprl lipoprotein from pseudomonas as a Th1 inducing natural adjuvant for heterologous antigens |
AU4831401A Pending AU4831401A (en) | 2000-02-18 | 2001-02-13 | TH1 inducing natural adjuvant for heterologous antigens |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU4831401A Pending AU4831401A (en) | 2000-02-18 | 2001-02-13 | TH1 inducing natural adjuvant for heterologous antigens |
Country Status (7)
Country | Link |
---|---|
US (1) | US6936263B2 (en) |
EP (1) | EP1255562B1 (en) |
AT (1) | ATE383871T1 (en) |
AU (2) | AU2001248314B2 (en) |
CA (1) | CA2400495A1 (en) |
DE (1) | DE60132427D1 (en) |
WO (1) | WO2001060404A2 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001248314B2 (en) * | 2000-02-18 | 2004-08-19 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Use of Oprl lipoprotein from pseudomonas as a Th1 inducing natural adjuvant for heterologous antigens |
US20030232055A1 (en) * | 2000-07-31 | 2003-12-18 | Ruslan Medzhitov | Innate immune system-directed vaccines |
US20030175287A1 (en) * | 2001-01-03 | 2003-09-18 | Yale University | Innate immune system-directed vaccines |
JP2005517674A (en) * | 2002-01-03 | 2005-06-16 | フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー | Novel immunoconjugates useful for tumor treatment |
EP1861426A4 (en) * | 2005-02-08 | 2008-11-12 | Queensland Inst Med Res | Immunogenic molecules |
EP1991264B1 (en) | 2006-03-07 | 2015-01-07 | Vaxinnate Corporation | Compositions that include hemagglutinin, methods of making and methods of use thereof |
US8466259B2 (en) * | 2007-12-07 | 2013-06-18 | National Health Research Institutes | Adjuvants |
US7833776B2 (en) | 2007-12-12 | 2010-11-16 | National Health Research Institutes | Lipidating sequences and use thereof for producing lipidated proteins in E. coli |
US8426163B2 (en) * | 2007-12-07 | 2013-04-23 | National Health Research Institutes | Production of lipidated proteins in E. coli |
ES2594102T3 (en) | 2008-04-18 | 2016-12-15 | Vaxinnate Corporation | Mutants by flagelin deletion and methods for its use |
US8287880B2 (en) | 2009-06-02 | 2012-10-16 | National Health Research Institutes | Lipidated vaccine against dengue virus infection |
CN102482327B (en) * | 2009-06-22 | 2014-10-29 | 财团法人卫生研究院 | Lipidated tumor- associated antigens and immunotherapeutic compositions and related method |
TW201221642A (en) | 2010-11-15 | 2012-06-01 | Nat Health Research Institutes | Method of producing lipidated polypeptides |
TWI507413B (en) | 2010-11-15 | 2015-11-11 | Nat Health Research Institutes | Lipidated polyepitope vaccines |
CN113150171B (en) * | 2021-04-25 | 2023-05-16 | 中国农业科学院兰州兽医研究所 | African swine fever virus recombinant protein containing intramolecular adjuvant, expression vector and application |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3829616C2 (en) * | 1988-09-01 | 1996-08-29 | Behringwerke Ag | Lipoprotein I (OMPI) from Pseudomonas aeruginosa |
FR2708622B1 (en) * | 1993-08-02 | 1997-04-18 | Raymond Hamers | Recombinant vector containing a sequence of a structural lipoprotein gene for the expression of nucleotide sequences. |
ATE190657T1 (en) * | 1994-12-16 | 2000-04-15 | Chiron Behring Gmbh & Co | IMMUNOGENIC HYBRID PROTEIN OPRF-OPRL AVAILABLE FROM MEMBRANE PROTEINS OF PSEUDOMONAS AERUGINOSA |
AU6280596A (en) * | 1995-06-15 | 1997-01-15 | University Of Victoria Innovation And Development Corporation | Mycobacterium tuberculosis dna sequences encoding immunostimlatory peptides |
US6638517B2 (en) * | 1995-09-22 | 2003-10-28 | Corixa Corporation | Leishmania antigens for use in the therapy and diagnosis of leishmaniasis |
US6607731B1 (en) * | 1995-09-22 | 2003-08-19 | Corixa Corporation | Leishmania antigens for use in the therapy and diagnosis of leishmaniasis |
US6613337B1 (en) * | 1997-02-12 | 2003-09-02 | Corixa Corporation | Leishmania antigens for use in the therapy and diagnosis of leishmaniasis |
US6541011B2 (en) * | 1998-02-11 | 2003-04-01 | Maxygen, Inc. | Antigen library immunization |
US6551795B1 (en) * | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
US6537552B1 (en) * | 1999-10-19 | 2003-03-25 | Iowa State University Research Foundation | Vaccine adjuvant |
AU2001248314B2 (en) * | 2000-02-18 | 2004-08-19 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Use of Oprl lipoprotein from pseudomonas as a Th1 inducing natural adjuvant for heterologous antigens |
-
2001
- 2001-02-13 AU AU2001248314A patent/AU2001248314B2/en not_active Ceased
- 2001-02-13 AU AU4831401A patent/AU4831401A/en active Pending
- 2001-02-13 CA CA002400495A patent/CA2400495A1/en not_active Abandoned
- 2001-02-13 WO PCT/EP2001/001673 patent/WO2001060404A2/en active IP Right Grant
- 2001-02-13 DE DE60132427T patent/DE60132427D1/en not_active Expired - Lifetime
- 2001-02-13 AT AT01921281T patent/ATE383871T1/en not_active IP Right Cessation
- 2001-02-13 EP EP01921281A patent/EP1255562B1/en not_active Expired - Lifetime
-
2002
- 2002-08-16 US US10/222,100 patent/US6936263B2/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001248314A1 (en) | Use of Oprl lipoprotein from pseudomonas as a Th1 inducing natural adjuvant for heterologous antigens | |
HUP0300099A3 (en) | Vaccine for the treatment of artherosclerosis | |
IL159209A0 (en) | Mutant forms of cholera holotoxin as an adjuvant | |
AU2002223504A1 (en) | Heterologous expression of taxanes | |
AU2001258279A1 (en) | Adjuvant for vaccines | |
HK1104319A1 (en) | Methods for the production of 3-o-deactivated-4'-monophosphoryl lipid a (3d-mla) | |
SI2255826T1 (en) | Neisserial vaccine compositions comprising a combination of antigens | |
AU2002348122A1 (en) | Waterless hand cleaner containing natural essential oil | |
IL127661A0 (en) | Induction of CTLs specific for natural antigens by cross-priming immunization | |
DE69405551D1 (en) | 3-0-DEACYLATED MONOPHOSPHORYL LIPID A CONTAINING VACCINE COMPOSITIONS | |
HUP0001403A3 (en) | Aqueous immunologic adjuvant compositions of monophosphoryl lipid a | |
HUP0300696A3 (en) | Proteins comprising conserved regions of neisseria meningitidis surface antigen nhha | |
EP1337149A4 (en) | Vaccine immunotherapy for immune suppressed patients | |
AU2002221519A1 (en) | Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens | |
WO2001060404A3 (en) | Use of opri lipoprotein from pseudomonas as a th1 inducing natural adjuvant for heterologous antigens | |
HUP0200583A3 (en) | A process for the preparation of aziridinyl epothilones from oxiranyl epothilones | |
GB0123756D0 (en) | A novel chaperone-type of adjuvant for vaccination - Basic 1 | |
IL149614A0 (en) | Novel use of antibodies as vaccines | |
HK1047034A1 (en) | Use of cpg as an adjuvant for malaria vaccine | |
AU2001293891A1 (en) | New combination for the treatment of asthma | |
AU7597501A (en) | Method for immuno-detection of epitopes | |
AU2002366544A1 (en) | Adjuvant formulations for bacterial and virus vaccines and method of making same | |
AU4621799A (en) | Use of an amphipathic compound for providing an adjuvant to subunit vaccine | |
AU2001286775A1 (en) | Adjuvant | |
EP1210364A4 (en) | Vaccine antigens of moraxella |